Pharvaris N.V. Stock Price, News & Analysis

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases like hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), has scheduled its annual general meeting of shareholders. The meeting will take place on June 27, 2025, at 16:00 CEST (10:00 a.m. EDT). Shareholders can access all relevant meeting documents and information in the "Investors" section of Pharvaris' website under "Events & Presentations" and on the SEC's website. Interested shareholders must register to attend as outlined in the meeting notice and agenda.

Pharvaris (PHVS) presented promising data for deucrictibant in treating bradykinin-mediated angioedema at the 14th C1-Inhibitor Deficiency Workshop. The drug showed strong efficacy in both prophylactic and on-demand treatment settings. In prophylaxis, long-term data revealed sustained attack rate reduction for over 18 months, with maintained quality of life improvements. The new extended-release (XR) formulation demonstrated 24-hour therapeutic coverage supporting once-daily dosing. For on-demand treatment, 95-100% of attacks showed durable response without symptom reoccurrence after a single dose, with median symptom relief onset of 1.1 hours. Notably, deucrictibant effectively treated upper airway attacks with 92.9% requiring only one dose. The company also validated a novel biomarker assay for bradykinin-mediated angioedema, potentially expanding treatment opportunities.

Pharvaris (PHVS) has announced multiple presentations of clinical data for deucrictibant at three major medical conferences in May-June 2025. The presentations will take place at the 14th C1-Inhibitor Deficiency and Angioedema Workshop in Budapest, the 2025 Eastern Allergy Conference in Palm Beach, and the EAACI Congress 2025 in Glasgow. Key presentations focus on deucrictibant's long-term safety and efficacy data from the CHAPTER-1 and RAPIDe-2 extension studies for both prophylaxis and treatment of hereditary angioedema (HAE) attacks. Notable topics include biomarker data, quality of life improvements, pharmacokinetics of the XR tablet formulation, and the CHAPTER-3 Phase 3 trial design. The company will make all presentation materials available on their investor relations website.

Pharvaris (PHVS) reported Q1 2025 financial results and provided updates on its development pipeline. The company is advancing deucrictibant, an oral bradykinin B2 receptor antagonist, through two pivotal Phase 3 studies: CHAPTER-3 for HAE attack prophylaxis and RAPIDe-3 for on-demand treatment. The FDA granted TQT study waivers for both deucrictibant formulations. Financial highlights include: cash position of €236M (down from €281M in Q4 2024), R&D expenses of €30.9M (up from €18.5M YoY), and a net loss of €46.3M (€0.85 per share). The company expects topline data from CHAPTER-3 in 2H2026 and will host an R&D call on June 4 to discuss expansion plans beyond HAE type 1/2.

Pharvaris (PHVS) has announced a virtual R&D call scheduled for June 4, 2025, at 8:00 a.m. ET/14:00 CET, titled "Deucrictibant: Beyond HAE Type 1/2". The event will focus on exploring the potential applications of deucrictibant, their oral bradykinin B2 receptor antagonist, beyond hereditary angioedema (HAE) Type 1/2.

The presentation will cover bradykinin-mediated angioedema's pathophysiology and prevalence, current treatment landscape, unmet needs, and Pharvaris' biomarker approach for disease identification. Key speakers include medical experts from Amsterdam UMC and Pharvaris' leadership team, including their CEO, CMO, and Chief Early Development Officer.

Pharvaris (PHVS) has achieved target enrollment in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for HAE attack treatment, while enrollment continues in CHAPTER-3 for HAE attack prophylaxis with topline data expected in 2H2026.

The company received European orphan medicinal product designation for deucrictibant in bradykinin-mediated angioedema treatment. Recent clinical data presentations showed promising results in long-term prophylaxis and rapid treatment of HAE attacks, including upper-airway attacks.

Financial highlights for FY2024:

• Cash position: €281 million (down from €391 million in 2023)
• R&D expenses: €98.6 million (up from €65.6 million in 2023)
• G&A expenses: €47.1 million (up from €31.3 million in 2023)
• Net loss: €134 million or €2.48 per share (compared to €100.9 million or €2.63 per share in 2023)

Pharvaris (Nasdaq: PHVS) announced that the European Commission (EC) has granted orphan designation to its investigational drug deucrictibant for treating bradykinin-mediated angioedema. This follows the U.S. FDA's orphan drug designation granted in March 2022.

The company is currently executing a phase 3 development program to evaluate deucrictibant's efficacy and safety in hereditary angioedema (HAE). As a bradykinin B2 receptor antagonist, deucrictibant aims to block bradykinin effects, potentially offering a broader-acting treatment option for bradykinin-mediated angioedema conditions beyond HAE. The company is also in discussions with regulators regarding a pivotal trial for acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).

Pharvaris (PHVS) presented long-term clinical data for deucrictibant in treating hereditary angioedema (HAE) at the 2025 AAAAI/WAO Joint Congress. Key findings from the CHAPTER-1 OLE study showed sustained protection from HAE attacks over 1.5 years, with the median proportion of days with symptoms reduced to zero. All participants reaching week 62 reported improved health-related quality of life.

In the RAPIDe-2 extension study, data from seven upper airway attacks showed a median time of 0.9 hours to symptom relief, consistent with results from 328 non-airway attacks. 85.7% of upper airway attacks were effectively treated with a single dose. The maximum exposure to deucrictibant was 20.8 months in the OLE study and 23.7 months overall, with no safety signals observed in both extension studies.

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference 2025. The conference will be held from March 10-12, 2025, at the W South Beach Hotel in Miami, FL.

The company, which specializes in treatments for bradykinin-mediated diseases including hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), will provide a live audio webcast of their presentation through their investor relations website. The recording will remain accessible for 30 days following the event.